<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pharmjournal</journal-id><journal-title-group><journal-title xml:lang="ru">Разработка и регистрация лекарственных средств</journal-title><trans-title-group xml:lang="en"><trans-title>Drug development &amp; registration</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2305-2066</issn><issn pub-type="epub">2658-5049</issn><publisher><publisher-name>LLC «CPHA»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33380/2305-2066-2023-12-3-151-168</article-id><article-id custom-type="elpub" pub-id-type="custom">pharmjournal-1554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ДОКЛИНИЧЕСКИЕ И КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PRECLINICAL AND CLINICAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Особенности набора пациентов в клинических исследованиях на примере международных мультицентровых клинических исследований (ММКИ)</article-title><trans-title-group xml:lang="en"><trans-title>Patterns of Patient Recruitment in Clinical Studies on the Example of International Multicenter Clinical Studies (IMCTs)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9843-6096</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Милованов</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Milovanov</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">milovanovss@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Индивидуальный предприниматель Милованов Святослав Сергеевич</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Sole entrepreneur Svyatoslav S. Milovanov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>31</day><month>08</month><year>2023</year></pub-date><volume>12</volume><issue>3</issue><fpage>151</fpage><lpage>168</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Милованов С.С., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Милованов С.С.</copyright-holder><copyright-holder xml:lang="en">Milovanov S.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmjournal.ru/jour/article/view/1554">https://www.pharmjournal.ru/jour/article/view/1554</self-uri><abstract><sec><title>Введение</title><p>Введение. Набор пациентов является одной из основных количественных и качественных характеристик клинического исследования. Как количественная характеристика набор пациентов – это в первую очередь конечная цифра, необходимая для ответа на вопрос исследователя, как качественная характеристика набор пациентов – это процесс, подверженный влиянию. Набор пациентов в центре определяется скоростью в месяц и позволяет набрать статистическую мощность протокола, и если набор пациентов не достигает запланированного, то мощность может быть не набрана и это приводит к неудаче клинического исследования. Неудачи в наборе пациентов, по данным литературы, ведут к более чем 80 % неудачных клинических исследований всех фаз. На набор пациентов как процесс влияют различные факторы, и авторы выделяют предикторы набора, фасилитаторы набора и барьеры к набору пациентов.</p></sec><sec><title>Цель</title><p>Цель. Рассмотреть общие особенности и закономерности набора пациентов в клинических исследованиях на примере международных мультицентровых клинических исследований.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Мы провели анализ количественных характеристик набора пациентов в 4 клинических исследованиях, успешных по набору пациентов.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Несмотря на уникальность каждого протокола, набор пациентов имеет свои закономерности, общие для всех клинических исследований. Изучено, в частности, что интегративная оценка предварительного набора пациентов исследователем клинического центра не связана с объективным пулом пациентов и влияет на скорость набора пациентов и на таргетный набор пациентов. Нами выявлено, что количество клинических центров, не набирающих пациентов, в каждом исследовании составляет не менее 30 % всех вовлеченных центров. Также выявлены три скорости набора пациентов, которые необходимо учитывать при планировании клинического исследования.</p></sec><sec><title>Заключение</title><p>Заключение. Мы выявили закономерности набора пациентов, которые помогут в планировании клинических исследований.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Introduction</title><p>Introduction. Patient recruitment is one of the main quantitative and qualitative characteristics of a clinical trial. As a quantitative characteristic, the recruitment of patients is, first of all, the final figure necessary to answer the researcher's question; as a qualitative characteristic, the recruitment of patients is a process subject to influence. The recruitment of patients in the center is determined by the rate per month and allows you to gain the statistical power of the protocol, and if the recruitment of patients does not reach the planned capacity, then the capacity may not be gained and this leads to the failure of the clinical trial. Failures in patient recruitment reported in the literature lead to more than 80 % of failed clinical trials of all phases. Patient recruitment as a process is influenced by various factors, and the authors identify recruitment predictors, recruitment facilitators, and barriers to patient recruitment.</p></sec><sec><title>Aim</title><p>Aim. To consider the general features and patterns of recruitment of patients in clinical trials on the example of international multicenter clinical trials.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We analyzed the quantitative characteristics of patient recruitment in 4 clinical trials with successful recruitment.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Despite the uniqueness of each protocol, the set of patients has its own patterns common to all clinical studies. It was studied, in particular, that the integrative assessment of the preliminary recruitment of patients by the researcher of the clinical center is not associated with an objective pool of patients and affects the rate of patient recruitment and targeted patient recruitment. We found that the number of clinical centers not recruiting patients in each study is at least 30 % of all centers involved. Three patient recruitment rates have also been identified that need to be considered when planning a clinical trial.</p></sec><sec><title>Conclusion</title><p>Conclusion. We have identified patterns in patient recruitment that will help in planning clinical trials.  </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>скорость набора пациентов</kwd><kwd>набор пациентов</kwd><kwd>клинические исследования</kwd><kwd>особенности набора пациентов</kwd><kwd>предварительная скорость набора пациентов</kwd></kwd-group><kwd-group xml:lang="en"><kwd>recruitment rate</kwd><kwd>recruitment</kwd><kwd>clinical trials</kwd><kwd>patterns of recruitment</kwd><kwd>proposed recruitment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Malgorzata M.-W. Patient-Centered Recruitment and Retention. Applied Clinical Trials. 2022. Available at: https://www.appliedclinicaltrialsonline.com/view/patient-centered-recruitment-and-retention. Accessed: 22.11.2022.</mixed-citation><mixed-citation xml:lang="en">Malgorzata M.-W. Patient-Centered Recruitment and Retention. Applied Clinical Trials. 2022. Available at: https://www.appliedclinicaltrialsonline.com/view/patient-centered-recruitment-and-retention. Accessed: 22.11.2022.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Crowther M. Phase 4 research: what happens when the rubber meets the road? Hematology. 2013;1:5–18. DOI: 10.1182/asheducation-2013.1.15.</mixed-citation><mixed-citation xml:lang="en">Crowther M. Phase 4 research: what happens when the rubber meets the road? Hematology. 2013;1:5–18. DOI: 10.1182/asheducation-2013.1.15.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang T. J., Carpenter D., Lauffenburger J. C., Wang B., Franklin J. M., Kesselheim A. S. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Medicine. 2016;176(12):1826–1833. DOI: 10.1001/jamainternmed.2016.6008.</mixed-citation><mixed-citation xml:lang="en">Hwang T. J., Carpenter D., Lauffenburger J. C., Wang B., Franklin J. M., Kesselheim A. S. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Medicine. 2016;176(12):1826–1833. DOI: 10.1001/jamainternmed.2016.6008.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fogel D. B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemporary Clinical Trials Communications. 2018;11:156–164. DOI: 10.1016/j.conctc.2018.08.001.</mixed-citation><mixed-citation xml:lang="en">Fogel D. B. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemporary Clinical Trials Communications. 2018;11:156–164. DOI: 10.1016/j.conctc.2018.08.001.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Woodin K. E., Schneider J. C. The CRA's Guide to Monitoring Clinical Research. Third Edition. Falls Church: CenterWatch. 2011. 678 p.</mixed-citation><mixed-citation xml:lang="en">Woodin K. E., Schneider J. C. The CRA's Guide to Monitoring Clinical Research. Third Edition. Falls Church: CenterWatch. 2011. 678 p.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Саватеев А. В., Белоцерковский М. В., Мосчицка К., Палумбо Д. Оценка физибильности как краеугольный камень успешного клинического исследования. Качественная клиническая практика. 2013;(2):37–46.</mixed-citation><mixed-citation xml:lang="en">Savateev A. V., Belotserkovsky M. V., Moscicka K., Palumbo D. Physical assessment as a cornerstone of a successful clinical trial. Kachestvennaya klinicheskaya praktika. 2013;(2):37–46. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">van den Bora R. M., Grobbee D. E., Oosterman B. J., Vaessen P. W. J., Roes K. C. B. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contemporary Clinical Trials Communications. 2017;7:208–216. DOI: 10.1016/j.conctc.2017.07.004.</mixed-citation><mixed-citation xml:lang="en">van den Bora R. M., Grobbee D. E., Oosterman B. J., Vaessen P. W. J., Roes K. C. B. Predicting enrollment performance of investigational centers in phase III multi-center clinical trials. Contemporary Clinical Trials Communications. 2017;7:208–216. DOI: 10.1016/j.conctc.2017.07.004.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Amsterdam: European Medicines Agency. 2018. 24 p. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf. Accessed: 22.11.2022.</mixed-citation><mixed-citation xml:lang="en">Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Amsterdam: European Medicines Agency. 2018. 24 p. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus_en.pdf. Accessed: 22.11.2022.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Reuter S., Chiu G. R. How effective are site questionnaires in predicting site performance? J. Clin. Res. Best Pract. 2007;3(4).</mixed-citation><mixed-citation xml:lang="en">Reuter S., Chiu G. R. How effective are site questionnaires in predicting site performance? J. Clin. Res. Best Pract. 2007;3(4).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wild C. P., Weiderpass E., Stewart B. W., editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon: International Agency for Research on Cancer. 2020. Available at: http://publications.iarc.fr/586. Accessed: 20.11.2022.</mixed-citation><mixed-citation xml:lang="en">Wild C. P., Weiderpass E., Stewart B. W., editors. World Cancer Report: Cancer Research for Cancer Prevention. Lyon: International Agency for Research on Cancer. 2020. Available at: http://publications.iarc.fr/586. Accessed: 20.11.2022.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А. Д., Старинский В. В., Шахзадова А. О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2021. 252 с.</mixed-citation><mixed-citation xml:lang="en">Kaprin A. D., Starinsky V. V., Shakhzadova A. O. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen branch of the National Medical Research Center for Radiology of the Ministry of Health of Russia. 2021. 252 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Мерабишвили В. М., Дятченко О. Т. Статистика Рака Легкого (заболеваемость, смертность, выживаемость). Практическая онкология. 2000;3:3–7.</mixed-citation><mixed-citation xml:lang="en">Merabishvili V. M., Diatchenko O. T. Lung Cancer Statistics (incidence, mortality, survival). Practical oncology. 2000;3:3–7. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249. DOI: 10.3322/caac.21660.</mixed-citation><mixed-citation xml:lang="en">Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249. DOI: 10.3322/caac.21660.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cox K., McGarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. European journal of cancer care. 2003;12(2):114–122. DOI: 10.1046/j.1365-2354.2003.00396.x.</mixed-citation><mixed-citation xml:lang="en">Cox K., McGarry J. Why patients don't take part in cancer clinical trials: an overview of the literature. European journal of cancer care. 2003;12(2):114–122. DOI: 10.1046/j.1365-2354.2003.00396.x.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jones R. H., White H., Velazquez E. J., Shaw L. K., Pietrobon R., Panza J. A., Bonow R. O., Spoko G., O'Connor C. M., Rouleau J.-L. STICH (surgical treatment for ischemic heart failure) trial enrollment. J. Am. Coll. Cardiol. 2010;56(6):490–498. DOI: 10.1016/j.jacc.2009.11.102.</mixed-citation><mixed-citation xml:lang="en">Jones R. H., White H., Velazquez E. J., Shaw L. K., Pietrobon R., Panza J. A., Bonow R. O., Spoko G., O'Connor C. M., Rouleau J.-L. STICH (surgical treatment for ischemic heart failure) trial enrollment. J. Am. Coll. Cardiol. 2010;56(6):490–498. DOI: 10.1016/j.jacc.2009.11.102.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bennette C. S., Ramsey S. D., McDermott C. L., Carlson J. J., Basu A., Veenstra D. L. Predicting low accrual in the National Cancer Institute's cooperative group clinical trials. Journal of the National Cancer Institute. 2016;108(2):djv324. DOI: 10.1093/jnci/djv324.</mixed-citation><mixed-citation xml:lang="en">Bennette C. S., Ramsey S. D., McDermott C. L., Carlson J. J., Basu A., Veenstra D. L. Predicting low accrual in the National Cancer Institute's cooperative group clinical trials. Journal of the National Cancer Institute. 2016;108(2):djv324. DOI: 10.1093/jnci/djv324.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bachenheimer B. J. F., Brescia B. A. Reinventing Patient Recruitment Revolutionary Ideas for Clinical Trial Success. New York: Routledge. 2007. 276 p.</mixed-citation><mixed-citation xml:lang="en">Bachenheimer B. J. F., Brescia B. A. Reinventing Patient Recruitment Revolutionary Ideas for Clinical Trial Success. New York: Routledge. 2007. 276 p.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kibby M. Models for success. Good Clinical Practice Journal. 2005;12(6):31–33.</mixed-citation><mixed-citation xml:lang="en">Kibby M. Models for success. Good Clinical Practice Journal. 2005;12(6):31–33.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yang E., O’Donovan C., Phillips J., Atkinson L., Ghosh K., Agrafiotis D. K. Quantifying and visualizing site performance in clinical trials. Contemporary Clinical Trials Communications. 2018;9:108–114. DOI: 10.1016/j.conctc.2018.01.005.</mixed-citation><mixed-citation xml:lang="en">Yang E., O’Donovan C., Phillips J., Atkinson L., Ghosh K., Agrafiotis D. K. Quantifying and visualizing site performance in clinical trials. Contemporary Clinical Trials Communications. 2018;9:108–114. DOI: 10.1016/j.conctc.2018.01.005.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf L. Expanding good recruitment practice. Journal of GXP compliance. 2007. P. 36–49.</mixed-citation><mixed-citation xml:lang="en">Wolf L. Expanding good recruitment practice. Journal of GXP compliance. 2007. P. 36–49.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Corrigan M. H., Glass H. E. Physician Participation in Clinical Studies and Subsequent Prescribing of New Drugs. Pharmacy and Therapeutics (P&amp;T). 2005;30(1):60–66.</mixed-citation><mixed-citation xml:lang="en">Corrigan M. H., Glass H. E. Physician Participation in Clinical Studies and Subsequent Prescribing of New Drugs. Pharmacy and Therapeutics (P&amp;T). 2005;30(1):60–66.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
